MTOR and nonpapillary renal cell carcinoma: It has been suggested that mutations in close upstream regulators of mTOR and loss of phosphatase and tensin homolog (PTEN) expression may be more reliable predictors of response to rapalogs than histological subtype.24 Thus, the selection of patients with ccRCC may not have been ideal for treatment with combination rapalog/mTOR inhibitors.